Nautilus Biotechnology reports FY2022 net loss of $57.9M; cash runway into 2025

Nautilus Biotechnology, Inc.

2022-FY EPS reported -$0.46

Net loss $57.9M for FY2022 vs $50.3M in FY2021; operating expenses $63.6M, up 26%.
Cash, cash equivalents, and investments $313.6M as of Dec 31, 2022; runway into 2025.
Strategic partnership with TGen to study Nautilus platform for DIPG childhood cancer.
Opened San Diego office in University Town Center to expand geographic footprint.
Q4 2022 expenses below peak Q4 2021 levels, helping preserve cash.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nautilus Biotechnology, Inc. reported the year-ended December 31, 2022 results: net income $57.9 million.

Period: the year-ended December 31, 2022
Net income: $57.9 million
Result: reported results

Exact text from the filing

Net loss was $57.9 million for the year-ended December 31, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.